• Correction: Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference

    Источник: Nasdaq GlobeNewswire / 27 апр 2023 10:14:23   America/New_York

    FORT LEE, NJ, April 27, 2023 (GLOBE NEWSWIRE) -- In the news release, Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference, please note that the conference date is May 2nd, 2023.  The complete, corrected release follows: 

    Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the H.C. Wainwright BioConnect Investor Conference at the NASDAQ world headquarters in New York City.

    EventH.C. Wainwright BioConnect Investor Conference at NASDAQ
    DateMay 2nd, 2023
    Time12:00 PM Eastern Time
    Linkhttps://journey.ct.events

    About Nuvectis Pharma

    Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is currently developing two drug candidates, NXP800 and NXP900. NXP800 is a clinical-stage, oral small molecule under development for the treatment of platinum-resistant, ARID1a-mutated ovarian carcinoma and additional solid tumor types. The United States Food and Drug Administration (“FDA”) granted Fast Track Designation to NXP800 for the treatment of platinum-resistant, ARID1a-mutated ovarian carcinoma. NXP900 is a novel, small molecule SRC/YES1 kinase inhibitor with an Investigational New Drug (“IND”) application pending.

    Nuvectis Pharma Contact:

    Ron Bentsur
    Chairman, Chief Executive Officer and President
    Tel: 201-614-3151
    rbentsur@nuvectis.com

    Media Relations Contact:

    Christopher M. Calabrese
    LifeSci Advisors
    Tel: 917-680-5608
    ccalabrese@lifesciadvisors.com


    Primary Logo

Опубликовать